OS1.7 Plasmatic differential scanning fluorimetry profiles discriminate glioma patients from healthy controls

由 Tabouret, E, Tsvetkov, P, Eyraud, R, Peel, T, Malesinski, S, Figarella-Branger, D, Chinot, O, Devred, F
發表在 Neuro Oncol (2019)

OS6.6 CEVOREM Trial: Combination of EVerolimus and Octreotide in REsistant MeningiomasPresentation and Preliminary results

由 Graillon, T., Peyre, M., Kalamarides, M., Sanson, M., Barrié, M., Campello, C., Tabouret, E., Roche, P., Dufour, H., Chinot, O.
發表在 Neuro Oncol (2016)

OS5.5 Characteristics of high-grade gliomas with H3 G34 mutation in adults

由 Picart, T, Barritault, M, Tabouret, E, Idbaih, A, Izquierdo Gracia, C, Poncet, D, Honnorat, J, Meyronet, D, Guyotat, J, Ducray, F
發表在 Neuro Oncol (2019)

P04.07 EXPRESSION PROFILE OF ANGIOGENIC FACTORS IN PAIRED INITIAL AND RECURRENT GLIOBLASTOMA

由 Tabouret, E., Tchoghandjian, A., Denicolai, E., Delfino, C., Metellus, P., Barrie, M., Boucard, C., Ouafik, L., Figarella-Branger, D., Chinot, O.
出版 2014

P04.08 PLASMA LEVELS AND TUMOR TISSUE RNA OF MMP2 AND MMP9 EXHIBIT SIMILAR DISTRIBUTION IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA (GB)

由 Tabouret, E., Boudouresque, F., Denicolai, E., Barrié, M., Boucard, C., Metellus, P., Autran, D., Figarella-Branger, D., Ouafik, L., Chinot, O.
出版 2014

P14.76 Characteristics of anaplastic oligodendrogliomas short-term survivors: a POLA network study

由 Garnier, L, Dehais, C, Curtit, E, Tabouret, E, Ramirez, C, Vauleon, E, Bourg, V, Boone, M, Figarella-Branger, D, Ducray, F
發表在 Neuro Oncol (2019)

P08.07 LEPTOMENINGEAL GLIOMATOSIS: A SINGLE INSTITUTION RETROSPECTIVE STUDY OF 31 PATIENTS

由 Autran, D., Tabouret, E., Barrié, M., Boucard, C., Terciolo, A., Loundou, A., Metellus, P., Dufour, H., Figarella-Branger, D., Chinot, O.L.
出版 2014

P17.20 PATTERNS OF CARE AND OUTCOME FOR PATIENTS WITH RECURRENT GLIOBLASTOMA

由 De Cock, L., Sala, Q., Barrie, M., Boucard, C., Metellus, P., Tabouret, E., Padovani, L., Figarella-Branger, D., Dufour, H., Chinot, O.
出版 2014

P14.118 Carboxypeptidase G2 (CPG2) rescue after high dose methotrexate (hdMTX) chemotherapy for Primary CNS Lymphoma (PCNSL). A French LOC network study

由 Garcilazo, Y J, Soussain, C, Tabouret, E, Ahle, G, Schimitt, A, Waultier, A, Blonski, M, Liou-Schischmanoff, A, Hoang-Xuan, K, Houillier, C
發表在 Neuro Oncol (2019)

P13.09 Genomic analysis of paired IDHwt glioblastoma (GB) reveals recurrent alterations of MPDZ at relapse after radiotherapy and temozolomide (RTCT)

由 Chanez, B, Appay, R, Guille, A, Lagarde, A, Bequet, C, Jiguet-Jiglaire, C, Graillon, T, Dufour, H, Figarella-Branger, D, Chinot, O, Tabouret, E
發表在 Neuro Oncol (2019)

Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152

由 Tchoghandjian, A, Soubéran, A, Tabouret, E, Colin, C, Denicolaï, E, Jiguet-Jiglaire, C, El-Battari, A, Villard, C, Baeza-Kallee, N, Figarella-Branger, D
發表在 Cell Death Dis (2016)

OS8.5 How to assess meningioma therapy activity: The CEVOREM independent central review experience

由 GRAILLON, T, Colin, T, Peyrière, H, Peyre, M, Tabouret, E, Campello, C, Idbaih, A, Boucekine, M, Figarella-Branger, D, Kalamarides, M, Dufour, H, Sanson, M, Chinot, O
發表在 Neuro Oncol (2019)

PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas

由 Appay, R, Dehais, C, Colin, C, Alentorn, A, Carpentier, C, Ducray, F, Ibdaih, A, Kamoun, A, Mokhtari, K, Tabouret, E, Uro-Coste, E, Delattre, J, Figarella-Branger, D
發表在 Neuro Oncol (2019)